KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Clinical trial NCT03662126 · UNKNOWN

Trial details

NCT number: NCT03662126
Sponsor: Kartos Therapeutics, Inc.
Status: UNKNOWN
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Primary Myelofibrosis (PMF)Post-Polycythemia Vera MF (Post-PV-MF)Post-Essential Thrombocythemia MF (Post-ET-MF)

Start date: 2019-01-15
Primary completion: 2023-12-31
Enrollment: 385

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.